These 'crazy' invasive Florida pests attack mammals, birds and create giant supercolonies
Meet tawny crazy ants.
They get their name from their erratic movements, especially while foraging, and are native to South America but spread to the southern U.S. in the late 1990s.
According to the USDA, tawny crazy ants in Florida are part of a super colony that spreads across the southern U.S. They lack territorial behavior, which enables the creation of gigantic supercolonies, whose need for resources drives out local wildlife and brings them into direct conflict with humans.
They can invade homes where they are drawn to and damage electrical equipment, and can make yards uncomfortable for residents to enjoy.
In areas of the country with severe tawny crazy ant infestations, they kill or displace local wildlife, including other ant species, even fire ants. 'There's no insect noise and there's no bird noise,' University of Texas ecologist Edward LeBrun told Science.
According to Texas A&M University's Urban and Structural Entomology Program, after experiencing the tawny crazy ant, most residents prefer the fire ant.
Tawny crazy ants bite and excrete formic acid
Tawny crazy ants bite and excrete formic acid, which they use like venom.
What do tawny crazy ants in Florida eat?
According to the University of Florida's Institute of Food and Agricultural Sciences (IFAS), tawny crazy ants prey on live animals, and scavenge from dead animals. They eat caterpillars, beetles, termites, wasps and spiders, or even small animals such as rabbits, birds, lizards, and domestic animals, which usually die due to asphyxia.
Tawny crazy ants are capable of forcing birds from their nests and blinding young rabbits with their acid, Smithsonian Magazine reported.
They can attack crops, domestic animals and honeybee hives, and take over the nesting sites of other ant species, including fire ants.
Where in Florida are tawny crazy ants found? See map
According to IFAS, by 2012, tawny crazy ants were found in 24 counties in Florida listed below, with infestations spreading. This can be expected in any county in Florida, IFAS reported.
Alachua
Brevard
Broward
Clay
Collier
DeSoto
Duval
Hardee
Hillsborough
Indian River
Lee
Manatee
Marion
Martin
Miami-Dade
Orange
Palm Beach
Pasco
Pinellas
Polk
Saint Johns
Saint Lucie
Sarasota
What do tawny crazy ants look like?
The Urban and Structural Entomology Program at Texas A&M University describes tawny crazy ants as follows:
Coloration: Adult colony members, including queens, males and workers, are reddish-brown (although lightness or darkness of their body color may vary)
Size: Worker ants are all similar in size (they are monomorphic), with a body length of 1/8 inch.
Worker ants have long legs and antennae and their bodies have numerous, long, coarse hairs. The antenna have 12-segments with no club.
There is a small circle of hairs (acidopore) present at tip of the abdomen (as opposed to the typical stinger found in many ants), a characteristic of formicine ants (found within the Formicinae subfamily).
How to get rid of tawny crazy ants around your home
Management of this ant will most likely require the services of a professional pest control company that practices integrated pest management (IPM).
According to UF, 100% eradication of this ant is not probable in areas where it is established. However, population suppression is possible.
Tawny crazy ant prevention
Schedule regular trash pick-up. Keep trash cans clean and stored away from the home.
Remove leaf litter, fallen branches, and other yard debris.
Keep hedges and trees trimmed so that they do not touch the home.
Eliminate or reduce possible food, water, and nesting sources.
Remove trash regularly and keep trash receptacles clean.
Do not leave dirty dishes in the sink.
Clean up spills immediately.
Place food items in the refrigerator or in sealed containers.
Pick up pet food bowls when your pet is not eating.
Exclusion
To prevent ants from entering a home:
Walk around the outside of the home and locate potential entry points (cracks, crevices, spaces around windows and doors).
Locate indoor entry points, paying particular attention to windows, doors, and plumbing and utility penetrations.
Use an appropriate sealant.
Replace door thresholds and weather stripping as needed.
If you can see light from the outside while you are standing inside, it is enough of a gap for ants and other pests to enter.
This article originally appeared on Palm Beach Post: Fire ant vs tawny ants: invasive species in Florida. Map, how to kill
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio'), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Senti Bio Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships. Availability of Other Information About Senti Biosciences, Inc. For more information, please visit the Senti Bio website at or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website ( including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Moleculin Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Founder, President, CEO and Chairman of Moleculin, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the segment, Mr. Klemp dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page of the Investors section of the Company's website ( About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data